Table 4.

Baseline characteristics associated with CKD progression (pooled placebo ITT population)

CharacteristiceGFR Decline (ml/min per 1.73 m2 per yr)P Values
eGFR Decline Fast Group (n=499;10.22±0.43)eGFR Decline Slow Group (n=500;0.28±0.26)
CKD cause
 Diabetic nephropathy214 (42.9)190 (38.0)0.12
 Nondiabetic nephropathy285 (57.1)310 (62.0)
CKD stage
 3a1 (0.2)2 (0.4)0.58
 3b69 (13.8)66 (13.2)
 4349 (69.9)343 (68.6)
 580 (16.0)89 (17.8)
sCr, mg/dl3.16±0.863.12±0.870.45
eGFR, ml/min per 1.73 m222.33±7.3421.76±7.120.21
UP/UCr2.41 (1.38); n=4981.60 (1.17); n=497<0.001
Hematuria
 Positive (+)214 (43.0)129 (25.8)<0.001
 Negative (–)284 (57.0)371 (74.2)
Systolic BP, mmHg135.2±13.6132.4±13.80.001
Diastolic BP, mmHg78.4±9.177.2±8.90.04
Age, yr53.4±15.4657.8±13.68<0.001
Sex
 Men320 (64.1)282 (56.4)0.01
Race
 White387 (77.6)398 (79.6)0.88
 Black or African American46 (9.2)43 (8.6)
 Asian22 (4.4)20 (4.0)
 Other44 (8.8)39 (7.8)
Use of ACEI or ARB
 Yes414 (83.0)427 (85.4)0.29
Baseline anemia statusa
 Yes365 (73.4)340 (68.8)0.11
Body mass index, kg/m2b28.6±6.429.6±7.90.03
  • Data are presented as n (%) or mean±SD. Median eGFR decline is –3.51 ml/min per 1.73 m2 per year (–0.292 ml/min per 1.73 m2 per month). Fast, <median; slow, ≥median. Hematuria (+): trace, 1+, 2+, or 3+.

  • a Anemia was defined as a hemoglobin level <13.5 g/dl (men) or <12.0 g/dl (women).

  • b Body mass index is weight in kilograms divided by square of the height in meters.